ALEC

Alector, Inc. operates as a clinical-stage biopharmaceutical company focused on developing therapies for neurodegeneration and cancer by leveraging insights into immune dysfunction and human genetics. Headquartered in South San Francisco, California, the company was founded in 2013 and employs approximately 250 people. Alector's proprietary platform centers on innate immunity, particularly targeting microglial and macrophage biology to address diseases including Alzheimer's, frontotemporal dementia, and amyotrophic lateral sclerosis. The company's pipeline includes multiple product candidates, with latozinemab (AL001) and AL101 in clinical trials for neurodegenerative conditions, and AL002 being developed for frontotemporal dementia. In immuno-oncology, Alector advances programs targeting myeloid cell function in the tumor microenvironment. The company maintains strategic collaborations with major pharmaceutical partners, including a collaboration with GSK valued at up to $2.2 billion in potential milestones for multiple programs. Alector operates under a business model that combines proprietary drug discovery with partnership-driven development, allowing it to advance a broad pipeline while sharing development costs and risks. The company reported approximately $63 million in collaboration revenue for 2022. Alector went public on the NASDAQ in 2019 and continues to invest heavily in clinical development as it progresses its lead candidates through mid-stage trials.